10P - Radiotherapy plus trastuzumab in the treatment of Her2-positive locally advanced breast cancer

Date 07 May 2015
Event IMPAKT 2015
Session Welcome reception and Poster Walk
Topics Anti-Cancer Agents & Biologic Therapy
Breast Cancer, Locally Advanced
Surgery and/or Radiotherapy of Cancer
Presenter Anna Belokhvostova
Citation Annals of Oncology (2015) 26 (suppl_3): 4-5. 10.1093/annonc/mdv114
Authors A. Belokhvostova, Y. Ragulin
  • Thoracic Department, A. Cyb Scientific Research Centre of Radiology of the Hertsen Federal Medical Research Centre, 249036 - Obninsk/RU



Aim: To evaluate the safety and efficacy of combined use of radiotherapy and targeted therapy with trastuzumab in the treatment of Her2-positive locally advanced breast cancer.

Materials and methods: The study included 57 patients with locally advanced non-inflammatory Her2-positive breast cancer. 30 of them received radiotherapy concurrently with trastuzumab (group A) and 27 without trastuzumab (group B). The main criterion for inclusion in the study was the absence of diseases of the cardiovascular system. 3-4 cycles of chemotherapy were carried out as induction. In case of absence of any effects or local progression the patient was administered radiotherapy (daily dose 2 Gy to a total dose of 60 Gy). Simultaneously with radiotherapy patients received chemotherapy with or without trastuzumab. The results of the treatment were evaluated 4 weeks after completion of radiotherapy. ECG and ECHO were evaluated at the total dose 30 Gy and 60 Gy.

Results: In the group A the frequency of clinical response was 93%, 82% regression of tumor more than 50% and 18% regression from 30% to 49%. In other cases the stabilization process was registered. In the group B, the comparable results were 74, 50 and 50%, respectively. Disease progression was registered during the therapy in one case. Patients with a good clinical effect underwent surgical treatment by radical mastectomy. The frequency of full morphological responses was higher in the group A and amounted to 37%, whereas in the group B this was 11%. Neither in the first nor in second group were adverse events resulting in acute heart failure observed. It was registered that one patient had a decrease in the ejection fraction of the left ventricle by 10% during the treatment. Other adverse events are similar in both groups and did not show significant differences.

Conclusion: Simultaneous use of radiotherapy and trastuzumab allows us to achieve better treatment results for patients with adverse prognostic forms of breast cancer. Due to the high risk of cardiotoxic effect this therapy must be justified and carried out under dynamic control.

Disclosure: All authors have declared no conflicts of interest.